Get the latest news, insights, and market updates on EVOK (Evoke Pharma, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Evoke Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update
Entered into an Agreement to be acquired by QOL Medical Net product sales for the third quarter of 2025 reached $4.3 million; up 61% year-over-year Gimoti patent life for Gimoti extended through November 2038 SOLANA BEACH, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI® (metoclopramide) nasal spray, today reported financial results for the third qu Nov 13, 2025 - $EVOK
UK Growth Companies With High Insider Ownership In November 2025
In November 2025, the United Kingdom's stock market is experiencing a challenging period, with the FTSE 100 and FTSE 250 indices reflecting concerns over weak global cues and faltering trade data from China. In such an environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business, potentially offering resilience amid broader market uncertainties. Nov 12, 2025 - $EVOK
Evoke Pharma Enters into Definitive Agreement to Be Acquired by QOL Medical
QOL Medical to Acquire All Outstanding Shares of Evoke for $11.00 Per Share in Cash Represents a 139.7% premium to most recent Nasdaq closing price Transaction expected to close by the end of 2025 SOLANA BEACH, Calif., and VERO BEACH, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK) (“Evoke”), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, and QOL Medical, LLC Nov 4, 2025 - $EVOK
UK Growth Stocks With Strong Insider Ownership
In recent weeks, the UK market has faced challenges, with the FTSE 100 index experiencing declines due to weak trade data from China and global economic uncertainties. As investors navigate these turbulent times, growth companies with strong insider ownership can offer a compelling opportunity, as such ownership often signals confidence in the company's long-term prospects and alignment of interests between management and shareholders. Sep 9, 2025 - $EVOK
Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship
Separately Secures Access to OneGI Through Brentwood Pharmacy Agreement Gimoti Specialty Pharmacy Network to Almost Double with Additional Relationships SOLANA BEACH, Calif. and CHICAGO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on developing treatments for gastrointestinal (GI) diseases, with a particular emphasis on GIMOTI® (metoclopramide) nasal spray, together with EVERSANA, a leading provider of global commercial services Aug 26, 2025 - $EVOK
Evoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange Book
SOLANA BEACH, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that U.S. Patent No. 12,377,064 covering the use of GIMOTI® (metoclopramide) nasal spray in patients with moderate to severe symptoms of gastroparesis, has been listed in the U.S. Food and Drug Administration’s (FDA) Approved Drug Pr Aug 21, 2025 - $EVOK
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple